Alert: Because flu cases are on the rise, children 12 and younger will be restricted from visiting hospitals and certain inpatient facilities. Learn more.

Research and Clinical Trials

STRIIVING (ViiV Healthcare 201147
Brief Description  
To determine the safety and efficacy of an experimental drug, abacavir/dolutegravir/lamivudine (ABC/DTG/3TC) fixed dose combination as a single tablet regimen compared with subjects taking their current combined antiretroviral therapy (cART) for the treatment of HIV-1 infected adults in whome the HIV-1 virus is currently suppressed.
Who may be Eligible  
Adults aged 18 or older; Agree not to become pregnant or father a child during the study term; Have an HIV viral load <50 for past 2 visits; Have been on current regimen for >6 months; Have stable maintenance labs; Not be on Dolutegravir (Tivicay) or Etravirine (Intelence); Normal EKG
Start Date  
IRB Number  
Principal Investigator  
Johnson, Marc
Contact Name  

For More Information, Contact  Jessica  A, Kearney-Bryan
Phone:  (704) 355-0244  Fax:  (704) 446-7641  
Email:  Jessica.Kearney-bryan@carolinas.org
Address:3rd Floor Myer's Park Clinic 1350 S. Kings Drive Charlotte, NC 28207